Showing results (11-20 of 867) with videos related to
Sort By:
Pageof 87
Biopharmaceutics & Drug Disposition|March 1, 1995
Uptake and biodisposition of 2-ylcyanamide-1,3,4-thiadiazole (LY217896) by red blood cellsP L Bonate, A PeytonJournal of Clinical Pharmacology|April 10, 1999
Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspectiveP L Bonate, T RussellClinical Pharmacokinetics|May 21, 1998
Drug interactions at the renal level. Implications for drug developmentP L Bonate, K Reith, S WeirPharmacology, Biochemistry, and Behavior|August 1, 1997
Behavioral sensitization to cocaine in the absence of altered brain cocaine levelsP L Bonate, A Swann, P B SilvermanLife Sciences|January 1, 1997
Context-dependent cross-sensitization between cocaine and amphetamineP L Bonate, A Swann, P B SilvermanJournal of Pharmaceutical Sciences|August 1, 1996
Preliminary physiologically based pharmacokinetic model for cocaine in the rat: model development and scale-up to humansP L Bonate, A Swann, P B SilvermanJournal of Chromatography. B, Biomedical Applications|July 21, 1995
High-performance liquid chromatographic assay for xanomeline, a specific M-1 agonist, and its metabolite in human plasmaS C Kasper, P L Bonate, A F DeLongJournal of Clinical Psychopharmacology|February 1, 2000
Clonazepam and sertraline: absence of drug interaction in a multiple-dose studyP L Bonate, P D Kroboth, R B Smith, et al.Biological Mass Spectrometry|October 1, 1994
Determination of xanomeline in human plasma by ion-spray tandem mass spectrometryA T Murphy, P L Bonate, S C Kasper, et al.Pageof 87